CytoDyn Inc. (CYDY) stock
CYDYOTCPharmaceutical PreparationsFiscal year ends May 31
$0.25+0.02 (+9.53%)
Close on Oct 19, 2026Market cap $345.56MP/E –Yield –
CytoDyn operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
CytoDyn's operating income for the twelve months ending Aug 31, 2026 was -$40.21M. For fiscal 2026 it was -$38.58M, down 499.3% from the year before. The highest annual figure on record is $9.66M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | May 31, 2026 | -$38.58M | -499.3% |
| FY2025 | May 31, 2025 | $9.66M | – |
| FY2024 | May 31, 2024 | -$18.06M | – |
| FY2023 | May 31, 2023 | -$40.58M | – |
| FY2022 | May 31, 2022 | -$145.40M | – |
| FY2021 | May 31, 2021 | -$104.60M | – |
| FY2020 | May 31, 2020 | -$74.65M | – |
| FY2019 | May 31, 2019 | -$55.85M | – |
| FY2018 | May 31, 2018 | -$45.92M | – |
| FY2017 | May 31, 2017 | -$27.33M | – |
| FY2016 | May 31, 2016 | -$21.18M | – |
| FY2015 | May 31, 2015 | -$19.60M | – |
| FY2014 | May 31, 2014 | -$8.11M | – |
| FY2013 | May 31, 2013 | -$7.99M | – |
| FY2012 | May 31, 2012 | -$7.46M | – |
| FY2011 | May 31, 2011 | -$3.70M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | -$6.58M | – |
| Q4 FY2026CQ2 2026 | May 31, 2026 | -$5.64M | – |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | -$6.30M | – |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | -$21.69M | – |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | -$4.95M | -122.0% |
| Q4 FY2025CQ2 2025 | May 31, 2025 | -$5.07M | – |
| Q3 FY2025CQ1 2025 | Feb 28, 2025 | -$4.00M | – |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | -$3.71M | – |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | $22.44M | – |
| Q4 FY2024CQ2 2024 | May 31, 2024 | -$6.63M | – |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | -$3.41M | – |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | -$3.40M | – |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | -$4.61M | – |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | -$23.16M | – |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | -$9.71M | – |
| Q4 FY2022CQ2 2022 | May 31, 2022 | -$79.05M | – |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | -$19.40M | – |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | -$25.32M | – |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | -$21.64M | – |
| Q4 FY2021CQ2 2021 | May 31, 2021 | -$23.64M | – |
| Q3 FY2021CQ1 2021 | Feb 28, 2021 | -$30.79M | – |
| Q2 FY2021CQ4 2020 | Nov 30, 2020 | -$24.50M | – |
| Q1 FY2021CQ3 2020 | Aug 31, 2020 | -$25.57M | – |
| Q4 FY2020CQ2 2020 | May 31, 2020 | -$27.82M | – |
| Q3 FY2020CQ1 2020 | Feb 29, 2020 | -$22.08M | – |
| Q2 FY2020CQ4 2019 | Nov 30, 2019 | -$12.12M | – |
| Q1 FY2020CQ3 2019 | Aug 31, 2019 | -$12.63M | – |
| Q4 FY2019CQ2 2019 | May 31, 2019 | -$13.80M | – |
| Q3 FY2019CQ1 2019 | Feb 28, 2019 | -$12.87M | – |
| Q2 FY2019CQ4 2018 | Nov 30, 2018 | -$15.69M | – |
| Q1 FY2019CQ3 2018 | Aug 31, 2018 | -$13.49M | – |
| Q4 FY2018CQ2 2018 | May 31, 2018 | -$11.20M | – |
| Q3 FY2018CQ1 2018 | Feb 28, 2018 | -$14.14M | – |
| Q2 FY2018CQ4 2017 | Nov 30, 2017 | -$10.78M | – |
| Q1 FY2018CQ3 2017 | Aug 31, 2017 | -$9.81M | – |
| Q4 FY2017CQ2 2017 | May 31, 2017 | -$7.80M | – |
| Q3 FY2017CQ1 2017 | Feb 28, 2017 | -$8.02M | – |
| Q2 FY2017CQ4 2016 | Nov 30, 2016 | -$6.16M | – |
| Q1 FY2017CQ3 2016 | Aug 31, 2016 | -$5.36M | – |
See a number that looks wrong?